Laddar...
Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a hematologic malignancy that affects predominantly older patients, with a median age of diagnosis around 67. Overall prognosis is poor; however, novel targeted therapies that can potentially improve outcomes in these patients have emerged in recent years. Mutations i...
Sparad:
| I publikationen: | J Adv Pract Oncol |
|---|---|
| Huvudupphovsmän: | , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Harborside Press
2018
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6347084/ https://ncbi.nlm.nih.gov/pubmed/30719396 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|